These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37864337)

  • 1. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
    Westin SN; Moore K; Chon HS; Lee JY; Thomes Pepin J; Sundborg M; Shai A; de la Garza J; Nishio S; Gold MA; Wang K; McIntyre K; Tillmanns TD; Blank SV; Liu JH; McCollum M; Contreras Mejia F; Nishikawa T; Pennington K; Novak Z; De Melo AC; Sehouli J; Klasa-Mazurkiewicz D; Papadimitriou C; Gil-Martin M; Brasiuniene B; Donnelly C; Del Rosario PM; Liu X; Van Nieuwenhuysen E;
    J Clin Oncol; 2024 Jan; 42(3):283-299. PubMed ID: 37864337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.
    Powell MA; Bjørge L; Willmott L; Novák Z; Black D; Gilbert L; Sharma S; Valabrega G; Landrum LM; Gropp-Meier M; Stuckey A; Boere I; Gold MA; Segev Y; Gill SE; Gennigens C; Sebastianelli A; Shahin MS; Pothuri B; Monk BJ; Buscema J; Coleman RL; Slomovitz BM; Ring KL; Herzog TJ; Balas MM; Grimshaw M; Stevens S; Lai DW; McCourt C; Mirza MR
    Ann Oncol; 2024 Aug; 35(8):728-738. PubMed ID: 38866180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.
    Bang YJ; Im SA; Lee KW; Cho JY; Song EK; Lee KH; Kim YH; Park JO; Chun HG; Zang DY; Fielding A; Rowbottom J; Hodgson D; O'Connor MJ; Yin X; Kim WH
    J Clin Oncol; 2015 Nov; 33(33):3858-65. PubMed ID: 26282658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Colombo N; Biagioli E; Harano K; Galli F; Hudson E; Antill Y; Choi CH; Rabaglio M; Marmé F; Marth C; Parma G; Fariñas-Madrid L; Nishio S; Allan K; Lee YC; Piovano E; Pardo B; Nakagawa S; McQueen J; Zamagni C; Manso L; Takehara K; Tasca G; Ferrero A; Tognon G; Lissoni AA; Petrella M; Laudani ME; Rulli E; Uggeri S; Barretina Ginesta MP;
    Lancet Oncol; 2024 Sep; 25(9):1135-1146. PubMed ID: 39102832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis.
    Bartoletti M; Montico M; Lorusso D; Mazzeo R; Oaknin A; Musacchio L; Scambia G; Puglisi F; Pignata S
    Cancer Treat Rev; 2024 Apr; 125():102701. PubMed ID: 38422895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.
    González-Martín A; Desauw C; Heitz F; Cropet C; Gargiulo P; Berger R; Ochi H; Vergote I; Colombo N; Mirza MR; Tazi Y; Canzler U; Zamagni C; Guerra-Alia EM; Levaché CB; Marmé F; Bazan F; de Gregorio N; Dohollou N; Fasching PA; Scambia G; Rubio-Pérez MJ; Milenkova T; Costan C; Pautier P; Ray-Coquard I;
    Eur J Cancer; 2022 Oct; 174():221-231. PubMed ID: 36067615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
    Ray-Coquard I; Leary A; Pignata S; Cropet C; González-Martín A; Marth C; Nagao S; Vergote I; Colombo N; Mäenpää J; Selle F; Sehouli J; Lorusso D; Guerra Alia EM; Bogner G; Yoshida H; Lefeuvre-Plesse C; Buderath P; Mosconi AM; Lortholary A; Burges A; Medioni J; El-Balat A; Rodrigues M; Park-Simon TW; Dubot C; Denschlag D; You B; Pujade-Lauraine E; Harter P;
    Ann Oncol; 2023 Aug; 34(8):681-692. PubMed ID: 37211045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
    Vergote I; Ray-Coquard I; Anderson DM; Cantuaria G; Colombo N; Garnier-Tixidre C; Gilbert L; Harter P; Hettle R; Lorusso D; Mäenpää J; Marth C; Matsumoto K; Ouwens M; Poveda A; Raspagliesi F; Rhodes K; Rubio Pérez MJ; Shapira-Frommer R; Shikama A; Sikorska M; Moore K; DiSilvestro P
    Eur J Cancer; 2021 Nov; 157():415-423. PubMed ID: 34597975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
    Rosenberg JE; Park SH; Kozlov V; Dao TV; Castellano D; Li JR; Mukherjee SD; Howells K; Dry H; Lanasa MC; Stewart R; Bajorin DF
    J Clin Oncol; 2023 Jan; 41(1):43-53. PubMed ID: 35737919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Bang YJ; Xu RH; Chin K; Lee KW; Park SH; Rha SY; Shen L; Qin S; Xu N; Im SA; Locker G; Rowe P; Shi X; Hodgson D; Liu YZ; Boku N
    Lancet Oncol; 2017 Dec; 18(12):1637-1651. PubMed ID: 29103871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P
    Lancet Oncol; 2021 Dec; 22(12):1721-1731. PubMed ID: 34715071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer.
    Hernando-Calvo A; Han M; Ayodele O; Wang BX; Bruce JP; Abbas-Aghababazadeh F; Vila-Casadesús M; Sanz-Garcia E; Yang SYC; Berman HK; Vivancos A; Lam B; Lungu I; Salawu A; Stayner LA; Haibe-Kains B; Bedard PL; Avery L; Razak ARA; Pugh TJ; Spreafico A; Siu LL; Hansen AR
    Clin Colorectal Cancer; 2024 Sep; 23(3):272-284.e9. PubMed ID: 38960798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
    Eskander RN; Sill MW; Beffa L; Moore RG; Hope JM; Musa FB; Mannel R; Shahin MS; Cantuaria GH; Girda E; Mathews C; Kavecansky J; Leath CA; Gien LT; Hinchcliff EM; Lele SB; Landrum LM; Backes F; O'Cearbhaill RE; Al Baghdadi T; Hill EK; Thaker PH; John VS; Welch S; Fader AN; Powell MA; Aghajanian C
    N Engl J Med; 2023 Jun; 388(23):2159-2170. PubMed ID: 36972022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
    Mirza MR; Chase DM; Slomovitz BM; dePont Christensen R; Novák Z; Black D; Gilbert L; Sharma S; Valabrega G; Landrum LM; Hanker LC; Stuckey A; Boere I; Gold MA; Auranen A; Pothuri B; Cibula D; McCourt C; Raspagliesi F; Shahin MS; Gill SE; Monk BJ; Buscema J; Herzog TJ; Copeland LJ; Tian M; He Z; Stevens S; Zografos E; Coleman RL; Powell MA;
    N Engl J Med; 2023 Jun; 388(23):2145-2158. PubMed ID: 36972026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
    Pignata S; Scambia G; Schettino C; Arenare L; Pisano C; Lombardi D; De Giorgi U; Andreetta C; Cinieri S; De Angelis C; Priolo D; Casanova C; Rosati M; Greco F; Zafarana E; Schiavetto I; Mammoliti S; Cecere SC; Salutari V; Scalone S; Farolfi A; Di Napoli M; Lorusso D; Gargiulo P; Califano D; Russo D; Spina A; De Cecio R; Chiodini P; Perrone F;
    Lancet Oncol; 2023 Mar; 24(3):286-296. PubMed ID: 37052965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
    Han HS; Diéras V; Robson M; Palácová M; Marcom PK; Jager A; Bondarenko I; Citrin D; Campone M; Telli ML; Domchek SM; Friedlander M; Kaufman B; Garber JE; Shparyk Y; Chmielowska E; Jakobsen EH; Kaklamani V; Gradishar W; Ratajczak CK; Nickner C; Qin Q; Qian J; Shepherd SP; Isakoff SJ; Puhalla S
    Ann Oncol; 2018 Jan; 29(1):154-161. PubMed ID: 29045554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.
    Ahn MJ; Bondarenko I; Kalinka E; Cho BC; Sugawara S; Gálffy G; Shim BY; Kislov N; Nagarkar R; Demedts I; Gans SJM; Mendoza Oliva D; Stewart R; Lai Z; Mann H; Shi X; Hussein M
    J Thorac Oncol; 2023 Nov; 18(11):1594-1606. PubMed ID: 37390980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
    Lee JM; Cimino-Mathews A; Peer CJ; Zimmer A; Lipkowitz S; Annunziata CM; Cao L; Harrell MI; Swisher EM; Houston N; Botesteanu DA; Taube JM; Thompson E; Ogurtsova A; Xu H; Nguyen J; Ho TW; Figg WD; Kohn EC
    J Clin Oncol; 2017 Jul; 35(19):2193-2202. PubMed ID: 28471727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.